GreenLight for Medical Cannabis in Europe (Health Europa article 9th July 2019)2019-07-10T17:25:43+00:00

GreenLight for Medical Cannabis in Europe

(Health Europa article 9th July 2019)

Established in 2014, GreenLight Pharmaceuticals Ltd is an Irish biopharmaceutical company focused on developing safe and effective plant based medicines. GreenLight specialises in phytocannabinoid research and clinical development. The company is based in Dublin, but has recently created a UK based subsidiary and has plans to expand into Europe.

‘Medical cannabis’ (cannabis based medical products (CBMP)) refers to a range of products that contain active compounds (primarily Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD)), either synthesised chemically, isolated from plant, or raw plant preparations.

In the past decade Germany, Italy, France, Spain and Switzerland have implemented medical cannabis access programmes for particular indications (Figure 1). In 2018 Ireland and UK also permitted medical use, however the prescribing process is still nascent, restricting access and uptake.

The Health Europa article briefly explores the current clinical evidence, issues in the UK and Irish patient access and medical education programmes, with GreenLight’s plans highlighted.

Figure 1.

GreenLight for Medical Cannabis in Europe (Health Europa article 8th July)